BPC-157 for tendon: what is the strongest version of the case, and where does it break?

Chronic achilles trouble, eighteen months, tried the boring things properly. BPC-157 is what the internet suggests and I would rather understand the argument than follow the crowd.

I have read the compound page and the evidence post. What I want from this thread is the strongest honest case for it, and then where that case actually fails. Not a yes or no.

Fair ask. The strongest honest case, stated properly:

The rodent tendon work is not nothing. There are transected achilles models where treated animals show better load-to-failure and better collagen organisation than controls, and the effect has been reported across several injury models — tendon, ligament, muscle, gut. There is a plausible mechanism in angiogenesis and fibroblast migration, and it is coherent with the healing biology rather than being invented afterwards to fit a result. It is also strikingly non-toxic in animals at doses far above anything used in practice.

That is a real case. If you had that dossier for a molecule you were taking into development, you would take it into development.

Where it breaks: that is where it stopped. No completed human trial. Not a failed one, not an ambiguous one — the step from "interesting in rats" to "tested in people" has not been taken in three decades. So the entire case rests on a translation step with a bad historical record, and it rests there indefinitely.

The independence problem sits on top of that. A large share of the corpus traces to one group. Replication by unrelated labs is the thing that turns an interesting result into a known one, and the ratio here is unusual.

Again: not an accusation. It is a structural fact about the evidence base that the paper count actively hides.

And the acute-harm item on the page is not a formality, so I will restate it rather than let the thread skip it.

The mechanism that plausibly helps a tendon is angiogenesis — new blood vessel growth. Solid tumours are limited by blood supply and recruit vessels to get past that limit. A systemically administered pro-angiogenic agent is therefore not a neutral thing to give someone with a personal or family history of cancer, and that is a conversation to have with a doctor before rather than after.

That is on the compound page under safety notes and it is there because it is real, not because the page is hedging.

That is the clearest version of it I have read, thank you. So: real biology, real animal signal, one lab doing a lot of the lifting, zero human trials, and a mechanism with a specific reason for caution in some people.

One more thing that is missing from the case and is missing from almost every discussion of it.

An eighteen-month achilles gets better sometimes. Tendinopathy has a long, erratic, spontaneously-improving natural history, and it fluctuates enough that whatever you happen to be doing when it turns is what gets the credit. Load management, deloading, time.

Which means even if you try it and improve, you will not learn anything. That is not a reason not to; it is a reason not to expect an answer at the end of it.

That is the bit I had genuinely not thought through. I would be running an uncontrolled experiment on a condition famous for getting better on its own.

Good thread, leaving it up as a model for how to ask this.

Noting for anyone arriving later: nobody in it told Gethin what to do, and that is not because we were being coy. It is rule 2. He has the case, the failure points and the specific caution, which is what a forum can honestly give him.